Therefore, whether anti-PD-1/PD-L1 ICIs can be applied to EGFR-TKI-sensitive patients, especially in EGFR-TKI-resistant NSCLC patients, remains to be further studied. Here, EGFR is linked to non-small cell lung carcinoma.